A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors



Status:Completed
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/3/2016
Start Date:June 2011
End Date:March 2014

Use our guide to learn which trials are right for you!

Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

This open-label 2-arm study will assess the pharmacokinetics, pharmacodynamics, safety and
efficacy of RO5429083 in patients with metastatic and/or locally advanced CD44-expressing
malignant solid tumors. In Part A, cohorts of patients will receive RO5429083 intravenously
at escalating doses. In Part B, patients will receive 89Zr-labelled RO5429083 in Cycles 1
and/or 2, followed by RO5429083. For all patients there will be an option to continue
treatment with RO5429083 until disease progression or unacceptable toxicity occurs.


Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Metastatic and/or locally advanced malignant CD44-expressing solid tumors

- Patients with disease progression on standard therapy, or have tumors that are not
curable by standard therapy

- Life expectancy of over 12 weeks

Exclusion Criteria:

- Concurrent therapy with any other investigational drug

- Known or suspected CNS metastases including leptomeningeal metastases

- Active bleeding, bleeding diathesis or history of coagulation disorder

- Uncontrolled diabetes mellitus

- Active or uncontrolled infections

- Patients with HIV infections
We found this trial at
3
sites
?
mi
from
Paris,
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials